HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

被引:250
作者
Sgadari, C
Barillari, G
Toschi, E
Carlei, D
Bacigalupo, I
Baccarini, S
Palladino, C
Leone, P
Bugarini, R
Malavasi, L
Cafaro, A
Falchi, M
Valdembri, D
Rezza, G
Bussolino, F
Monini, P
Ensoli, B
机构
[1] Ist Super Sanita, Virol Lab, I-00161 Rome, Italy
[2] Ist Super Sanita, Epidemiol & Biostat Lab, I-00161 Rome, Italy
[3] Ist Super Sanita, Lab Ultrastruct, I-00161 Rome, Italy
[4] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy
[5] Univ Turin, Dept Oncol Sci, Inst Canc Res & Treatment, Turin, Italy
关键词
D O I
10.1038/nm0302-225
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Treatment with HIV-1 protease inhibitors (PI) is associated with a reduced incidence or regression of Kaposi sarcoma (KS). Here we show that systemic administration of the PIs indinavir or saquinavir to nude mice blocks the development and induces regression of angioproliferative KS-like lesions promoted by primary human KS cells, basic fibroblast growth factor (bFGF), or bFGF and vascular endothelial growth factor (VEGF) combined. These PIs also block bFGF or VEGF-induced angiogenesis in the chorioallantoic membrane assay with a potency similar to paclitaxel (Taxol). These effects are mediated by the inhibition of endothelial- and KS-cell invasion and of matrix metalloproteinase-2 proteolytic activation by PIs at concentrations present in plasma of treated individuals. As PIs also inhibit the in vivo growth and invasion of an angiogenic tumor-cell line, these data indicate that PIs are potent anti-angiogenic and anti-tumor molecules that might be used in treating non-HIV KS and in other HIV-associated tumors.
引用
收藏
页码:225 / 232
页数:8
相关论文
共 50 条
[21]   TAT PROTEIN OF HIV-1 STIMULATES GROWTH OF CELLS DERIVED FROM KAPOSIS-SARCOMA LESIONS OF AIDS PATIENTS [J].
ENSOLI, B ;
BARILLARI, G ;
SALAHUDDIN, SZ ;
GALLO, RC ;
WONGSTAAL, F .
NATURE, 1990, 345 (6270) :84-86
[22]   BLOCK OF AIDS-KAPOSIS SARCOMA (KS) CELL-GROWTH, ANGIOGENESIS, AND LESION FORMATION IN NUDE-MICE BY ANTISENSE OLIGONUCLEOTIDE TARGETING BASIC FIBROBLAST GROWTH-FACTOR - A NOVEL STRATEGY FOR THE THERAPY OF KS [J].
ENSOLI, B ;
MARKHAM, P ;
KAO, V ;
BARILLARI, G ;
FIORELLI, V ;
GENDELMAN, R ;
RAFFELD, M ;
ZON, G ;
GALLO, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (05) :1736-1746
[23]   Kaposi's sarcoma:: A result of the interplay among inflammatory cytokines, angiogenic factors and viral agents [J].
Ensoli, B ;
Stürzl, M .
CYTOKINE & GROWTH FACTOR REVIEWS, 1998, 9 (01) :63-83
[24]   Reactivation and role of HHV-8 in Kaposi's sarcoma initiation [J].
Ensoli, B ;
Stürzl, M ;
Monini, P .
ADVANCES IN CANCER RESEARCH, VOL 81, 2001, 81 :161-200
[25]  
Fiorelli V, 1998, BLOOD, V91, P956
[26]   Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function. [J].
Gruber, A ;
Wheat, JC ;
Kuhen, KL ;
Looney, DJ ;
Wong-Staal, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (51) :47840-47843
[27]   Development of matrix metalloproteinase inhibitors in cancer therapy [J].
Hidalgo, M ;
Eckhardt, SG .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (03) :178-193
[28]   Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs - Implications for potential therapy [J].
Kedes, DH ;
Ganem, D .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (09) :2082-2086
[29]   Tumor targeting with a selective gelatinase inhibitor [J].
Koivunen, E ;
Arap, W ;
Valtanen, H ;
Rainisalo, A ;
Medina, OP ;
Heikkilä, P ;
Kantor, C ;
Gahmberg, CG ;
Salo, T ;
Konttinen, YT ;
Sorsa, T ;
Ruoslahti, E ;
Pasqualini, R .
NATURE BIOTECHNOLOGY, 1999, 17 (08) :768-774
[30]   Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma [J].
Lebbé, C ;
Blum, L ;
Pellet, C ;
Blanchard, G ;
Vérola, O ;
Morel, P ;
Danne, O ;
Calvo, F .
AIDS, 1998, 12 (07) :F45-F49